跳至主要内容
临床试验/ACTRN12616001679471
ACTRN12616001679471已完成未知

A Cross-Sectional study to explore the correlation between PET SUVR and amyloid-beta plaques in the retina, identified by fluorescence imaging using the EidonTM (RetiaTM) retinal imaging system with and without curcumin labeling.

euroVision Imaging LLC0 个研究点目标入组 286 人开始时间: 2016年12月6日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
286

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis

入排标准

年龄范围
60 Years 至 o limit(—)
性别
All

入选标准

  • 1. Enrolled in the AIBL study with a A Ddiagnosis of MCI, or healthy controls within 36 months as per the AIBL criteria at the screening visit .
  • 2. PET amyloid brain scan within 36 months of baseline visit
  • 3.Participant must be able to provide written informed consent in English.
  • 4. Male or Female age 60 years or older at the screening visit
  • 5. In the opinion of the retinal photographer, clear ocular media and pupillary dilation to allow for ocular imaging

排除标准

  • 1.The participant has advanced retinal disease, advanced cataracts or other advanced ocular conditions that in the opinion of the investigator are likely to affect obtaining clear images of the retina.
  • 2. Participant has had prior ocular surgery within 2 months of planned retinal imaging, or is still taking post-operative ocular medications at first day of retinal imaging.
  • 3. Participants with known current gallstone.
  • 4. Participants who have undergone angioplasty in the last 3 months.
  • 5Participants who have had major surgery within 4 weeks of trial inclusion or planned surgical procedure during the trial period.
  • 6. Significant haemorrhagic event (in past 12 months) or cardiovascular disease ( ie, history of myocardial infarction within past 6 months of trial inclusion, congestive cardiac failure NYHA grade II ).
  • 7.Participant with retinitis pigmentosa.
  • 8. Participants with current bile duct obstruction (participants who have undergone a cholecystectomy will be considered eligible).
  • 9. Participants with significant uncontrolled gastrointestinal disorders (including stomach ulcers and uncontrolled hyperacidity disorders) which in the opinion of the investigator will be aggravated by the intake of curcumin.
  • 10. Participants with known allergy to Tropicamide eye drops, Vitamin E or turmeric.
  • 11.Participation in another clinical trial within 30 days prior to visit one (with the exception of the AIBL trial).
  • 12. In the opinion of the investigator, the participant’s cognitive function is no longer consistent with the AIBL diagnosis.

研究者

发起方
euroVision Imaging LLC

相似试验